M
Mark D. Johnson
Researcher at University of Massachusetts Medical School
Publications - 301
Citations - 18425
Mark D. Johnson is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 60, co-authored 289 publications receiving 16103 citations. Previous affiliations of Mark D. Johnson include National Institutes of Health & Georgetown University Medical Center.
Papers
More filters
Journal Article
The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa.
TL;DR: Rolipram is more effective than salmeterol in preventing P. aeruginosa-induced epithelial damage and agents that elevate intracellular cAMP protect the epithelium during bacterial infection.
Journal ArticleDOI
Alpha 1 adrenergic receptor function in senescent Fischer 344 rat aorta.
Mark D. Johnson,Arlene Wray +1 more
TL;DR: Results suggest that aortic alpha 1 receptor-mediated formation of inositol phosphate intracellular second messengers is enhanced during aging, despite this, the capacity of senescent arteries to elicit contraction utilizing second messenger pathways seems to be deficient.
Journal ArticleDOI
Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints
TL;DR: In this article , the impact of tumor invasion, the molecular and cellular heterogeneity of the tumor, and the blood-brain barrier on the delivery and distribution of drugs using potential therapeutic delivery options such as convection-enhanced delivery, controlled release systems, nanomaterial systems, peptide-based systems, and focused ultrasound.
Journal ArticleDOI
Mechanisms of neuronal cell death
Richard S. Morrison,Yoshito Kinoshita,Hong Xiang,Mark D. Johnson,Charles Kuntz,Saadi Ghatan,Joseph T. Ho,Philip A. Schwartzkroin +7 more
Journal ArticleDOI
Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone
Nils D. Arvold,Diana D. Shi,Ayal A. Aizer,Ayal A. Aizer,Andrew D. Norden,David A. Reardon,Eudocia Q. Lee,Lakshmi Nayak,Ian F. Dunn,Ian F. Dunn,Alexandra J. Golby,Alexandra J. Golby,Mark D. Johnson,Mark D. Johnson,Elizabeth B. Claus,Elizabeth B. Claus,Elizabeth B. Claus,E. Antonio Chiocca,E. Antonio Chiocca,Keith L. Ligon,Keith L. Ligon,Patrick Y. Wen,Brian M. Alexander,Brian M. Alexander +23 more
TL;DR: Survival after re-irradiation for recurrent HGG appears independent of dose/fractionation and compares favorably with bevacizumab alone, as well as among patients with a local-only recurrence.